AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific drug delivery technology, offers improved medical benefits and a potential for significant commercial development.
AlphaRx Appoints President for its China Operations
“The Company is poised to become a leading drug developer in the pharmaceutical market in China and I’m looking forward to playing a major part in AlphaRx’s future and driving this company to new heights …”
Hong Kong – December 14, 2009 – AlphaRx Inc. (OTCBB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology [...]
AlphaRx Establishes Corporate Headquarters in Hong Kong and R&D Facility in Shanghai
Markham, Canada (December 3, 2009) – AlphaRx Inc. (OTCBB: ALRX), today announced that it has selected locations in Hong Kong and Shanghai for its corporate headquarters and a new R&D facility respectively. This initiative will spearhead a major push into Greater China.
The R&D facility will be located in The State Biotech Pharmaceutical industrial base (Shanghai) [...]
AlphaRX Review
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. [This appears on the bottom of their press releases.]
As can be seen on the [...]
AlphaRx and Riso Pharma Sign Collaboration and Licensing Agreement
MARKHAM, Ontario, September 30, 2009 – AlphaRx Inc., has entered into an exclusive collaboration and licensing agreement with Riso Pharma Tech for the development of ARX606T, an early stage product candidate intended for wound treatment.
Under the terms of the agreement, AlphaRx will give Riso exclusive global rights (with
the exception of Asia) of ARX606T, which makes [...]
